Some issues of methotrexate pneumonitis in rheumatoid arthritis
- Authors: Bestaev D.V1, Ktsoeva S.A1, Brtsieva Z.S1, Khutieva L.M1, Osipova L.V1, Burduli N.N1, Kotsoeva O.T1, Bestaeva T.D2
-
Affiliations:
- North Ossetian State Medical Academy
- Family Medicine Clinic
- Issue: Vol 26, No 11 (2019)
- Pages: 69-72
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312276
- DOI: https://doi.org/10.18565/pharmateca.2019.11.69-72
- ID: 312276
Cite item
Abstract
Keywords
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
D. V Bestaev
North Ossetian State Medical Academy
Email: dayidbestaev@rambler.ru
MD, Head of the Department of Internal Diseases № 3 Vladikavkaz, Russia
S. A Ktsoeva
North Ossetian State Medical AcademyVladikavkaz, Russia
Z. S Brtsieva
North Ossetian State Medical AcademyVladikavkaz, Russia
L. M Khutieva
North Ossetian State Medical AcademyVladikavkaz, Russia
L. V Osipova
North Ossetian State Medical AcademyVladikavkaz, Russia
N. N Burduli
North Ossetian State Medical AcademyVladikavkaz, Russia
O. T Kotsoeva
North Ossetian State Medical AcademyVladikavkaz, Russia
T. D Bestaeva
Family Medicine ClinicVladikavkaz, Russia
References
- Насонов Е.Л., Насоновa В.А. Ревматология: Национальное руководство М., 2008.
- Caporali R., Cavagna L., Montecucco C. Pain in arthritis. Eur J. Pain. 2009;3(Suppl. 2):123-27. doi: 10.1016/j.eujps.2009.07.009
- Govoni M., Caporali R. Predicting and managing the progression of structural damage in rheumatoid arthritis: where do we stand? Clin Exp Rheumatol. 2012;30(4):459-63.
- Krishnan E., Lingala B., Bruce B., Fries J.F. Disability in rheumatoid arthritis in the era of biological treatments. Ann Rheum Dis. 2012;71(4):213 18. doi: 10.1136/annrheumdis2011-200354
- Gabriel S.E., Crowson C.S., Kremers H.M., et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthr Rheum. 2003;48(1):54-8. doi: 10.1002/art.10705.
- Cimmino M.A., Salvarani C., Macchioni P, et al. Extra-articular manifestations in 587 Italian patients with rheumatoid arthritis. Rheumatol Int. 2000;19(6):213-17. Doi: 10.1007/ PL00006853.
- Cavagna L., Boffini N., Cagnotto G., et al. Atherosclerosis and rheumatoid arthritis: more than a simple association. Mediators Inflamm. 2012;2012:147354. doi: 10.1155/2012/147354.
- Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol. 2013;25(3):360-66. Doi: W.W97/BOR.0b013e32835f693f.
- Gauhar U.A., Gaffo A.L., Alarcon G.S. Pulmonary manifestations of rheumatoid arthritis. Semin Respir Crit Care Med. 2007;28(4):430-40. doi: 10.1055/s-2007-985664.
- Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best practice and research. Clin Rheumatol. 2007;21(5):907-27. Doi: 10.1016/j. berh.2007.05.007.
- De Lauretis A., Veeraraghavan S., Renzoni E. Connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis. 2011;8(1):53-82. doi: 10.1177/1479972310393758.
- Ellman P., Ball R. Rheumatoid arthritis with joint and pulmonary manifestations. Br Med J. 1948;2(4583):816-20. Doi: 10.1136/ bmj.2.4583.816.
- Бестаев Д.В., Каратеев Д.Е., Насонов Е.Л. Интерстициальное поражение легких у больных ревматоидным артритом в эру применения генно-инженерных биологических препаратов. Клиническая фармакология и терапия. 2013;22(1):55-61.
- Kim E.J., Elicker B.M., Maldonado F., et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6): 1322-28. doi: 10.1183/09031936.00092309.
- Ascherman D.P. Interstitial lung disease in rheumatoid arthritis. Curr Rheumatol Rep. 2010;12(5):363-69. doi: 10.1007/s11926-010-0116-z.
- Hunninghake G.W., Fauci A.S. Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis. 1979;119(3):471-503. doi: 10.1164/arrd.1979.119.3.471.
- Cervantes-Perez P., Toro-Perez A.H., Rodriguez-Jurado P. Pulmonary involvement in rheumatoid arthritis. J. Am Med Association. 1980;243(17):1715-19. Doi: 10.1001/ jama.243.17.1715.
- Mori S., Koga Y., Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med. 2012;106(11):1591-99. Doi: 10.1016/j. rmed.2012.07.006.
- Saag K.G., Kolluri S., Koehnke R.K., et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthr Rheum. 1996;39(10):1711-19. Doi: 10.1002/ art.1780391014.
- Koduri G., Norton S., Young A., et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatol. (Oxford). 2010;49(8): 1483-89. doi: 10.1093/rheumatology/keq035.
- Bongartz T., Nannini C., Medina-Velasquez Y.F., et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis - a population-based study. Arthr Rheum. 2010;62(6):1583-91. doi: 10.1002/art.27405.
- Toyoshima M., Chida K., Suda T., Sato M. Methotrexate might increase mortality from interstitial lung disease in rheumatoid arthritis. Am J Respir Crit Care Med. 2012;185(9):1024. doi: 10.1164/ajrccm.185.9.1024.
- Inokuma S. Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic druginduced lung injury. Exp Opin Drug Safety 2011;10(4):603-11. doi: 10.1517/14740338.2011.560835.
- Perez-Alvarez R., Perez-de-Lis M., Diaz-Lagares C., et al. interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthr Rheum. 2011;41(2):256-64. doi: 10.1016/j.semarthrit 2010.11.002.
- Panopoulos S.T., Sfikakis PP Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med. 2011;17(5):362-67. Doi: 10.1097/ MCP0b013e3283483ea5.
- Acute lymphocytic leukemia in children: maintenance therapy with methotrexate administered intermittently. Acute leukemia Group B. JAMA. 1969;207(5):923-28. Doi: 10.1001/ jama.1969.03150180053011.
- Engelbrecht J.A., Calhonn S.L., Scherrer J.J. Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis. Arthr Rheum. 1983;26:1275-78. Doi: 10.1002/ art.1780261016.
- Imokawa S., Colby T.V., Leslie K.O., Helmers R.A. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000;15:373-81.
- Salliot C., van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009;68:1100-104. doi: 10.1136/ard.2008.093690.
- Kinder A.J., Hassell A.B., Brand J., et al. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatol. (0xford).2005;44:61-6. doi: 10.1093/rheumatology/keh512.
- Conway R., Low C., Cotighian R.J., et al. Methotrexate and interstitial lung disease in rheumatoid arthritis a systematic literature review and meta-analysis. Arthr Rheum. 2012;64:5918. doi: 10.1002/art.38322.
- Alarcon G.S, Kremer J.M., Macaluso M., et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997;127:356-64. doi: 10.7326/0003-4819-127-5-199709010 00003.
- Bedrossian C.W., Miller W.C., Luna M.A. Methotrexate-induced diffuse interstitial pulmonary fibrosis. South Med J. 1979;72:313 18. doi: 10.1097/00007611-197903000 00023
- Cannon G.W, Ward J.R., Clegg D.O., et al. Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthr Rheum. 1983;26:269-74. doi: 10.1002/art.1780261015.
- Collins K, Aspey H., Todd A., et al. Methotrexate pneumonitis precipitated by switching from oral to parenteral administration. Rheumatol. (Oxford). 2008;47:109-10. doi: 10.1093/rheumatology/ kem230.
- Barrera P., van Ede A.E., Laan R.F., et al. Methotrexate-related pulmonary complications in patients with rheumatoid arthritis; cluster of five cases in a period of three months. Ann Rheum Dis. 1994;53:479-30. Doi: 10.1136/ ard.53.7.479.
- Kremer J.M., Alarcon G.S., Weinblatt M.E., et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-assonated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthr Rheum. 1997;40:1829-37. Doi: 10.1002/ art.1780401016.
- van der Veen M.J., Dekker J.J., Dmant H.J., et al. Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. J Rheumatol. 1995;22:1766-68.
- Dawson J.K., Graham D.R., Desmond J., et al. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatol. (0xford).2002;41:262-67. Doi: 10.1093/ rheumatology/41.3.262.
- Beyeler C., Jordi B., Gerber N.J., ImHof V. Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol. 1996;35:446-52.
- Cottin V, Tebib J., Massonnet B., et al. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest. 1996;109:933-38. doi: 10.1378/chest.109.4.933.
- Cook N.J., Carroll G.J. Successful reintroduction of methotrexate after pneumonitis in two patients with rheumatoid arthritis. Ann Rheum Dis. 1992;51:272-74. doi: 10.1136/ard.51.2.272.
- Khadadah M.E., Jayakrishnan B., AI-Gorair S., et al. Effect of methotrexate on pulmonary function in patients with rheumatoid arthritis a prospective study. Rheumatol. 2002;22:204-7. doi: 10.1007/s00296-002-0227-6.
- Iikuni N., Kitahama M., Ohta S., et al. Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheumatol. 2006;16(5):282-88. Doi: 10.1007/ s10165-006-0502-6.
- Hsu PC., Lan J.L. Hsieh T.Y, et al. Methotrexate pneumonitis in a patient with rheumatoid arthritis. J Microbiol Immunol Infect. 2003;36:137-40.
- Arakawa H., Yamasaki M., Kurihara Y., et al. Methotrexate-induced pulmonary injury: serial CT findings. J Thorac Imaging. 2003;18(4):231-36.
- Ohosone Y, Okano Y, Kameda H., et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol. 1997;24(12):2299-303.
- Lateef O., Shakoor N., Balk K.A. Methotrexate pulmonary toxicity. Expert Opin Drug Saf. 2005;4(4):723-30. doi: 10.1517/14740338.4.4.723.
- Leduc D., De Vuyst P., Lheureux P., et al. Pneumonitis complicating low-dose methotrexate therapy for rheumatoid arthritis. Discrepancies between lung biopsy and bronchoalveolar lavage findings. Chest. 1993; 104(5): 1620-23. Doi: 10.1378/ chest.104.5.1620.
- Golden M.R., Katz R.S., Balk R., Golden H.E. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol. 1995;22(6):1043-47.
- Carson C.W, Cannon G.W., Egger M.J., et al. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthr Rheum. 1987;16(3):186-95.
Supplementary files
![](/img/style/loading.gif)